Bsteh, Gabriel
Macher, Stefan
Krajnc, Nik
Marik, Wolfgang
Michl, Martin
Müller, Nina
Zaic, Sina
Harreiter, Jürgen
Novak, Klaus
Wöber, Christian
Pemp, Berthold
Article History
Received: 28 March 2024
Accepted: 23 April 2024
First Online: 7 May 2024
Declarations
:
: <b>Gabriel Bsteh</b>: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis.<b>Stefan Macher</b>: declares no conflict of interest relevant to this study.<b>Nik Krajnc</b>: has participated in meetings sponsored by, received speaker honoraria or travel funding from Alexion, BMS/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).<b>Wolfgang Marik</b>: declares no conflict of interest relevant to this study.<b>Martin Michl</b>: declares no conflict of interest relevant to this study.<b>Nina Müller</b>: declares no conflict of interest relevant to this study.<b>Sina Zaic</b>: declares no conflict of interest relevant to this study.<b>Jürgen Harreiter</b>: declares no conflict of interest relevant to this study.<b>Klaus Novak</b>: declares no conflict of interest relevant to this study.<b>Christian Wöber</b>: has received honoraria consultancy/speaking from Apomedica, Curelator, Eli Lilly, Grünenthal, Hermes, Lundbeck, Novartis, Pfizer, Ratiopharm/Teva, and Stada.<b>Berthold Pemp</b>: has received honoraria for consultancy/speaking from Chiesi, GenSight, Novartis and Santen.